10779/rcsi.10768169.v1
Marta Zapotoczna
Marta
Zapotoczna
Éanna Forde
Éanna
Forde
Siobhan Hogan
Siobhan
Hogan
Hilary Humphreys
Hilary
Humphreys
James P O'Gara
James P
O'Gara
Deirdre Fitzgerald-Hughes
Deirdre
Fitzgerald-Hughes
Marc Devocelle
Marc
Devocelle
Eoghan O'Neill
Eoghan
O'Neill
Eradication of Staphylococcus aureus Biofilm Infections Using Synthetic Antimicrobial Peptides.
Royal College of Surgeons in Ireland
2019
Animals
Anti-Bacterial Agents
Biofilms
Catheter-Related Infections
Cytokines
Disease Models
Animal
Humans
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Peptides
Cyclic
Rats
Sprague-Dawley
Staphylococcal Infections
Vancomycin
Clinical Microbiology
2019-11-22 15:19:18
Journal contribution
https://repository.rcsi.com/articles/journal_contribution/Eradication_of_Staphylococcus_aureus_Biofilm_Infections_Using_Synthetic_Antimicrobial_Peptides_/10768169
<p>Here, we demonstrate that antimicrobial peptides (AMPs) are an effective antibiofilm treatment when applied as catheter lock solutions (CLSs) against S. aureus biofilm infections. The activity of synthetic AMPs (Bac8c, HB43, P18, Omiganan, WMR, Ranalexin, and Polyphemusin) was measured against early and mature biofilms produced by methicillin-resistant S. aureus and methicillin-susceptible S. aureus isolates from patients with device-related infections grown under in vivo-relevant biofilm conditions. The cytotoxic and hemolytic activities of the AMPs against human cells and their immunomodulatory potential in human blood were also characterized. The D-Bac8c2,5Leu variant emerged as the most effective AMP during in vitro studies and was also highly effective in eradicating S. aureus biofilm infection when used in a CLS rat central venous catheter infection model. These data support the potential use of D-Bac8c2,5Leu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter infections.</p>